Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J. Oreja-Guevara C, et al. Among authors: pilo de la fuente b. Mult Scler Relat Disord. 2024 Oct;90:105787. doi: 10.1016/j.msard.2024.105787. Epub 2024 Aug 2. Mult Scler Relat Disord. 2024. PMID: 39142050 Free article.
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espiño M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, Pilo de la Fuente B, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM. Monreal E, et al. Among authors: pilo de la fuente b. Brain. 2024 Dec 3;147(12):4084-4093. doi: 10.1093/brain/awae260. Brain. 2024. PMID: 39101570
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sainz de la Maza S, Sabin Muñoz J, Pilo de la Fuente B, Thuissard I, Andreu-Vázquez C, Galán Sánchez-Seco V, Salgado-Cámara P, Costa-Frossard L, Monreal E, Ayuso-Peralta L, García-Vasco L, García-Domínguez JM, Martínez-Ginés ML, Muñoz Fernández C, Díaz-Díaz J, Oreja-Guevara C, Gómez-Moreno M, Martín H, Rubio-Flores L, Blasco MR, Villar-Guimerans LM, Aladro Y; Dimethyl Fumarate Study Group. Sainz de la Maza S, et al. Among authors: pilo de la fuente b. Mult Scler Relat Disord. 2022 Mar;59:103669. doi: 10.1016/j.msard.2022.103669. Epub 2022 Feb 4. Mult Scler Relat Disord. 2022. PMID: 35150979
Response to the effect of pharmacologic treatment of migraine on retinal vasculature.
González-Martín-Moro J, Porta Etessam J, Pilo de la Fuente B, Fuentes Vega I, Contreras I. González-Martín-Moro J, et al. Among authors: pilo de la fuente b. Eur J Ophthalmol. 2022 Jan;32(1):NP340. doi: 10.1177/11206721211028042. Epub 2021 Jun 27. Eur J Ophthalmol. 2022. PMID: 34180258 No abstract available.
Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment.
Gómez-Moreno M, Sánchez-Seco VG, Moreno-García S, Cámara PS, Sabin-Muñoz J, Ayuso-Peralta L, Oreja-Guevara C, Díaz-Díaz J, Sainz de la Maza S, Costa-Frossard L, Pilo de la Fuente B, Aladro-Benito Y. Gómez-Moreno M, et al. Among authors: pilo de la fuente b. Mult Scler Relat Disord. 2021 Apr;49:102747. doi: 10.1016/j.msard.2021.102747. Epub 2021 Jan 11. Mult Scler Relat Disord. 2021. PMID: 33524928
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
Pilo de la Fuente B, Sabín J, Galán V, Thuissard I, Sainz de la Maza S, Costa-Frossard L, Gómez-Moreno M, Díaz-Díaz J, Oreja-Guevara C, Lozano-Ros A, García-Domínguez JM, Borrego L, Ayuso L, Castro A, Sánchez P, Meca-Lallana V, Muñoz C, Casanova I, López de Silanes C, Martín H, Rodríguez-García E, Andreu-Vázquez C, Blasco R, García-Merino JA, Aladro Y; Dimethyl Fumarate Study Group. Pilo de la Fuente B, et al. CNS Drugs. 2020 Dec;34(12):1275-1286. doi: 10.1007/s40263-020-00775-9. Epub 2020 Nov 23. CNS Drugs. 2020. PMID: 33226562
Disc Configuration as a Risk and Prognostic Factor in NAION: The Impact of Cup to Disc Ratio, Disc Diameter, and Crowding Index.
González Martín-Moro J, Contreras I, Gutierrez-Ortiz C, Gómez-Sanz F, Castro-Rebollo M, Fernández-Hortelano A, Pilo-De-La-Fuente B. González Martín-Moro J, et al. Among authors: pilo de la fuente b. Semin Ophthalmol. 2019;34(3):177-181. doi: 10.1080/08820538.2019.1620792. Epub 2019 Jun 4. Semin Ophthalmol. 2019. PMID: 31162995
45 results